Table 1.
Association between clinicopathological parameters and EGFR, HER2, and HER3 expression in 121 cases of gastric cancer
| Parameters | n | EGFR-positive (%) | P-value | HER2-positive (%) | P-value | HER3-positive (%) | P-value |
|---|---|---|---|---|---|---|---|
| N | 121 | 40 (33.1%) | 21 (17.4%) | 76 (66.1%) | |||
| Sex | |||||||
| Male | 85 | 28 (32.9%) | 0.8062 | 16 (22.9%) | 0.1971 | 52 (65.8%) | 0.6439 |
| Female | 36 | 12 (33.3%) | 5 (15.6%) | 23 (67.6%) | |||
| Tumor grade | |||||||
| II | 23 | 6 (26.1%) | 0.439 | 11 (55.0%) | 0.0001 | 18 (78.3%) | 0.285 |
| III | 87 | 30 (34.5%) | 10 (13.7%) | 53 (64.6%) | |||
| IV | 11 | 3 (27.3%) | 0 (0%) | 5 (62.5%) | |||
| Tumor stage | |||||||
| I and II | 36 | 6 (16.7%) | 0.0146 | 5 (15.6%) | 0.2689 | 23 (65.7%) | 0.9817 |
| III | 61 | 23 (37.7%) | 14 (28.6%) | 37 (67.3%) | |||
| IV | 24 | 11 (45.8%) | 2 (9.5%) | 15 (65.2%) | |||
| Depth of invasion | |||||||
| T1 and T2 | 11 | 0 (0%) | 0.0001 | 4 (40.0%) | 0.3389 | 8 (66.7%) | 0.6825 |
| T3 and T4 | 110 | 40 (36.4%) | 17 (18.5%) | 67 (66.3%) | |||
| Lymph node metastasis | |||||||
| 0 | 31 | 6 (19.4%) | 0.0783 | 3 (11.1%) | 0.1874 | 17 (58.6%) | 0.3989 |
| 1 | 48 | 15 (31.3%) | 12 (30.0%) | 32 (71.1%) | |||
| 2 | 22 | 10 (45.5%) | 4 (23.5%) | 12 (60.0%) | |||
| 3 | 20 | 9 (45.0%) | 2 (11.1%) | 14 (73.7%) | |||
| Metastasis | |||||||
| Negative | 112 | 36 (32.1%) | 0.8115 | 21 (22.1%) | 0.1049 | 70 (67.3%) | 0.672 |
| Positive | 9 | 4 (44.4%) | 0 (0%) | 5 (55.6%) | |||
| Subtype | |||||||
| Intestinal type | 24 | 10 (41.7%) | 0.282 | 9 (37.5%) | 0.064 | 20 (83.3%) | 0.0859 |
| Diffused type or mixed type | 95 | 28 (29.5%) | 12 (15.4%) | 55 (63.2%) | |||
Note: T1–T4 is the tumor stage based on tumor-node-metastasis classification advocated by International Union against Cancer.
Abbreviations: EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; n, number.